Every 8-K that CytomX Therapeutics, Inc. (CTMX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CTMX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTMX filings page.
CytomX Therapeutics reported Q2 2026 total revenue of $1.4 million, down from $18.7 million a year earlier, as prior collaboration obligations with Bristol Myers Squibb and Astellas wound down. Total operating expenses rose to $25.2 million from $19.9 million, leading to a net loss attributable to common stockholders of $20.7 million versus a net loss of $0.2 million in Q2 2025.
The company ended June 30, 2026 with $330.3 million in cash, cash equivalents and investments and expects this to fund operations to at least the second half of 2028; this excludes a $37.0 million target selection payment received in July from Regeneron under an expanded bispecific immunotherapy collaboration that allows for up to approximately $4.0 billion in potential milestones. CytomX advanced its varsetatug masetecan (Varseta‑M) colorectal cancer program toward a planned first registrational study in the first half of 2027, broadened monotherapy and combination trials into additional gastrointestinal tumors, and continued early-stage development of CX‑801 in advanced melanoma.
CytomX Therapeutics, Inc. appointed Charles Fuchs, M.D., M.P.H., to its Board of Directors as a Class II director, effective July 24, 2026, with an initial term running until the company’s 2029 annual meeting of stockholders. He will receive the company’s standard non-employee director compensation.
Upon joining the board, Dr. Fuchs was granted an option to purchase 118,000 shares of common stock under the 2015 Equity Incentive Plan, with an exercise price equal to the closing price on July 24, 2026. The option vests as to 1/36th of the shares each month, subject to his continued service. The company will also enter into its standard indemnification agreement with him and states there are no related-party transactions over $120,000 or special arrangements connected to his appointment.
CytomX Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where stockholders approved several governance and equity-related proposals. The company later filed a charter amendment to reflect these changes.
Stockholders approved an amendment to the Amended and Restated 2015 Equity Incentive Plan to increase the number of shares authorized for issuance under the plan by 6,500,000 shares, and an amendment to the Amended and Restated Employee Stock Purchase Plan to increase shares authorized thereunder by 1,000,000 shares. Both amendments were previously adopted by the board and became effective upon stockholder approval.
Stockholders also approved a charter amendment increasing the authorized number of shares of common stock from 300,000,000 to 600,000,000 shares. All management proposals, including the election of two Class II directors, ratification of Ernst & Young LLP as auditor, executive compensation on an advisory basis, and holding future say-on-pay votes every year, received sufficient support, with broker non-votes recorded where applicable.
CytomX Therapeutics updated its cancer drug collaboration with Regeneron through Amendment No. 4 to their 2022 Collaboration and License Agreement. The amendment, effective May 31, 2026, extends the period in which Regeneron can select additional drug programs and allows for up to eight more collaboration programs.
Regeneron has already nominated the first two of these additional programs, which entitle CytomX to receive $37.0 million in aggregate target nomination payments. Across all potential programs, the Agreement provides for up to approximately $4 billion in target nomination, preclinical, clinical, regulatory and commercial milestone payments, while previously disclosed tiered royalty terms remain unchanged.
CytomX Therapeutics reported Q1 2026 revenue of $10.3 million and a net loss of $18.2 million, compared with $50.9 million of revenue and $23.5 million of net income a year earlier. The drop in revenue primarily reflects completion of collaboration performance obligations in 2025.
Cash, cash equivalents and investments rose to $346.7 million as of March 31, 2026, helped by a $250 million equity follow-on offering, giving an expected cash runway to at least the second half of 2028. The company highlighted positive Phase 1 data and completed 40‑patient dose optimization enrollment for its EpCAM ADC Varseta‑M in advanced colorectal cancer, and ongoing development of CX‑801, including a KEYTRUDA® combination study in melanoma.
CytomX Therapeutics completed an underwritten equity financing built around a large common stock and warrant sale. The company issued 45,990,567 shares of common stock at $5.30 per share and pre-funded warrants to purchase 1,179,245 shares at $5.29999 per warrant, with underwriters holding a 30-day option to buy up to 7,075,471 additional shares at the public price.
The transaction closed on March 19, 2026 and is expected to generate approximately $234.4 million in net proceeds after underwriting discounts and expenses. CytomX plans to use the cash to continue developing Varseta-M, advance other pipeline programs, and for general corporate and working capital purposes.
CytomX Therapeutics reported 2025 results showing a sharp revenue decline alongside progress in its oncology pipeline. Revenue was $76.2 million for 2025, down from $138.1 million in 2024, mainly due to completion and slower recognition of collaboration revenues. Total operating expenses fell to $98.6 million from $113.1 million, but the company moved from net income of $31.9 million in 2024 to a net loss of $17.4 million in 2025, or $(0.15) per share.
CytomX ended 2025 with $137.1 million in cash, cash equivalents and investments, up from $100.6 million, and expects its cash runway to extend to the second quarter of 2027. Clinically, the company announced positive Phase 1 dose-expansion data for Varseta-M in advanced colorectal cancer and is targeting 2026 FDA interactions to align on a potential registrational trial. Combination studies of Varseta-M with bevacizumab and chemotherapy are underway or planned. The CX-801 interferon alpha-2b program in advanced melanoma is advancing through Phase 1, including a combination with KEYTRUDA, with initial combination data expected by the end of 2026.
CytomX Therapeutics, Inc. filed a current report to let investors know it has released unaudited financial results for the third quarter and first nine months of 2025. The company did this through a press release dated November 6, 2025, which also includes a broader business update.
The press release is furnished as Exhibit 99.1 to the report, meaning it is provided for information but is not treated as formally filed for liability purposes under certain securities laws. CytomX’s common stock continues to trade on the Nasdaq Global Select Market under the symbol CTMX.
On August 13, 2025, CytomX Therapeutics provided an update on its CX-2051 Phase 1 study. Dose expansions at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg, given every three weeks, have each enrolled approximately 20 patients as planned. The company reported a single Grade 5 treatment-related acute kidney injury in a patient with a complex medical history, including a solitary kidney; the event was believed to be secondary to nausea, vomiting and diarrhea and was reported to the FDA on July 18, 2025. The study's Safety Review Committee convened on July 14, 2025 and supported continued study execution and enrollment.
The CTMX-2051-101 study remains ongoing and a Phase 1 data update is expected by Q1 2026. The filing discloses enrollment progress, the serious adverse event and regulatory reporting but does not provide additional efficacy or broader safety data.